Publications by authors named "Doris Phelps"

Claim this Profile
M
MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57 targeting.
Silvia Pomella, Matteo Cassandri, Lucrezia D'Archivio, Antonella Porrazzo, Cristina Cossetti, Doris Phelps

Nat Commun· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Redundant Signaling as the Predominant Mechanism for Resistance to Antibodies Targeting the Type-I Insulin-Like Growth Factor Receptor in Cells Derived from Childhood Sarcoma.
Terry J Shackleford, Seethalakshmi Hariharan, Angelina V Vaseva, Karina Alagoa, Maricruz Espinoza, Doris A Phelps

Mol Cancer Ther· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell RNA profiling identifies diverse cellular responses to EWSR1/FLI1 downregulation in Ewing sarcoma cells.
Roxane Khoogar, Fuyang Li, Yidong Chen, Myron Ignatius, Elizabeth R Lawlor, Doris A Phelps

Cell Oncol (Dordr)· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surfaceome Profiling of Rhabdomyosarcoma Reveals B7-H3 as a Mediator of Immune Evasion.
Roxane R Lavoie, Patricio C Gargollo, Mohamed E Ahmed, Yohan Kim, Emily Baer, Doris A Phelps

Cancers (Basel)· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of VTP-50469, a menin-MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium.
Raushan T Kurmasheva, Abhik Bandyopadhyay, Edward Favours, Vanessa Del Pozo, Samson Ghilu, Doris A Phelps

Pediatr Blood Cancer· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts.
Andrew J Robles, Raushan T Kurmasheva, Abhik Bandyopadhyay, Doris A Phelps, Stephen W Erickson

Clin Cancer Res· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models.
Raushan T Kurmasheva, Abhik Bandyopadhyay, Edward Favours, Vanessa Del Pozo, Samson Ghilu, Doris A Phelps

Pediatr Blood Cancer· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis.
Amy C Gross, Hakan Cam, Doris A Phelps, Amanda J Saraf, Hemant K Bid

JCI Insight· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models.
Abhik Bandyopadhyay, Edward Favours, Doris A Phelps, Vanessa Del Pozo, Samson Ghilu

Pediatr Blood Cancer· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma.
Hemant K Bid, Doris A Phelps, Linlin Xaio, Denis C Guttridge, Jiayuh Lin

Mol Cancer Ther· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma.
Adam Studebaker, Kathryn Bondra, Star Seum, Changxian Shen, Doris A Phelps

Pediatr Blood Cancer· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma.
Doris Phelps, Kathryn Bondra, Star Seum, Christopher Chronowski, Justin Leasure

Pediatr Blood Cancer· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma.
Hemant K Bid, Aaron Kibler, Doris A Phelps, Sagymbek Manap, Linlin Xiao

Clin Cancer Res· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks.
Changxian Shen, Duane Oswald, Doris Phelps, Hakan Cam, Christopher E Pelloski

Cancer Res· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.
Richard Gorlick, E Anders Kolb, Peter J Houghton, Christopher L Morton, Geoffrey Neale, Doris Phelps

Pediatr Blood Cancer· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2.
Hemant K Bid, Jun Zhan, Doris A Phelps, Raushan T Kurmasheva, Peter J Houghton

Mol Cancer Ther· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program.
Peter J Houghton, Richard Gorlick, E Anders Kolb, Richard Lock, Hernan Carol, Doris Phelps

Pediatr Blood Cancer· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.
Peter J Houghton, Richard Lock, Hernan Carol, Christopher L Morton, Doris Phelps

Pediatr Blood Cancer· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.
E Anders Kolb, Richard Gorlick, Peter J Houghton, Christopher L Morton, Geoffrey Neale, Doris Phelps

Pediatr Blood Cancer· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program.
Richard Gorlick, E Anders Kolb, Peter J Houghton, Christopher L Morton, Doris Phelps

Pediatr Blood Cancer· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
ICAM-2 expression mediates a membrane-actin link, confers a nonmetastatic phenotype and reflects favorable tumor stage or histology in neuroblastoma.
Karina Jin Yoon, Doris A Phelps, Rebecca A Bush, Joanna S Remack, Catherine A Billups

PLoS One· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.
Malcolm A Smith, Christopher L Morton, Doris A Phelps, E Anders Kolb, Richard Lock

Pediatr Blood Cancer· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular characterization of the pediatric preclinical testing panel.
Geoffrey Neale, Xiaoping Su, Christopher L Morton, Doris Phelps, Richard Gorlick

Clin Cancer Res· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SK-NEP-1 and Rh1 are Ewing family tumor lines.
Malcolm A Smith, Christopher L Morton, Doris Phelps, Kevin Girtman, Geoffrey Neale

Pediatr Blood Cancer· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a tumor-selective approach to treat metastatic cancer.
Karen S Aboody, Rebecca A Bush, Elizabeth Garcia, Marianne Z Metz, Joseph Najbauer, Doris A Phelps

PLoS One· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis